Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)
5.97
+0.09 (1.53%)
Apr 29, 2026, 4:00 PM EDT
SHA:688373 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 307.95 | 316.1 | 386.26 | 166.31 | 151.09 | 145.52 |
Trading Asset Securities | 112.91 | 135.54 | 207.36 | 786.98 | 1,119 | 326.36 |
Cash & Short-Term Investments | 420.86 | 451.64 | 593.62 | 953.3 | 1,270 | 471.88 |
Cash Growth | -29.92% | -23.92% | -37.73% | -24.95% | 169.17% | -25.92% |
Accounts Receivable | 39.65 | 37.96 | 31.88 | 21.98 | 11.1 | 1.42 |
Other Receivables | 20.21 | 20.52 | 21.02 | 0.19 | 0.34 | 0 |
Receivables | 59.86 | 58.47 | 52.9 | 22.17 | 11.44 | 1.42 |
Inventory | 44.4 | 50.25 | 52.94 | 37.52 | 21.89 | 11.01 |
Other Current Assets | 70.62 | 62.09 | 49.21 | 41.27 | 67.01 | 25.29 |
Total Current Assets | 595.74 | 622.46 | 748.66 | 1,054 | 1,371 | 509.59 |
Property, Plant & Equipment | 61.86 | 61.73 | 75.8 | 86.21 | 97.46 | 122.8 |
Other Intangible Assets | 0.81 | 0.95 | 1.68 | 1.93 | 2.19 | 0.84 |
Long-Term Deferred Charges | 15.28 | 16.04 | 19.1 | 21.75 | 22.68 | 1.83 |
Other Long-Term Assets | 3.91 | 3.91 | 3.89 | 4.42 | 4.54 | 13.48 |
Total Assets | 677.59 | 705.09 | 849.13 | 1,169 | 1,497 | 648.54 |
Accounts Payable | 73.42 | 16.57 | 26.21 | 11.13 | 10.85 | 1.91 |
Accrued Expenses | 2.72 | 96.51 | 78.63 | 94.51 | 37.41 | 29.45 |
Short-Term Debt | 25.02 | 25.02 | 5 | - | 48.75 | 50.08 |
Current Portion of Long-Term Debt | 140.06 | 68.42 | 89.23 | 14.15 | 10.1 | - |
Current Portion of Leases | - | 12.77 | 11.51 | 10.38 | 6.47 | 11.04 |
Current Income Taxes Payable | 20.16 | 0.2 | - | 4.41 | - | - |
Current Unearned Revenue | 5.19 | 0.47 | - | 0.13 | - | - |
Other Current Liabilities | 21.46 | 4.42 | 1.71 | 1.93 | 1.52 | 1.71 |
Total Current Liabilities | 288.02 | 224.38 | 212.3 | 136.65 | 115.11 | 94.19 |
Long-Term Debt | 139.44 | 213.04 | 122.94 | 114.96 | 70 | - |
Long-Term Leases | 66.45 | 60.38 | 73.18 | 81.7 | 94.89 | 99.87 |
Long-Term Unearned Revenue | 1.75 | 1.75 | 1.75 | 1.25 | 3.1 | 16.1 |
Total Liabilities | 495.66 | 499.55 | 410.16 | 334.56 | 283.1 | 210.17 |
Common Stock | 656.23 | 656.23 | 655.61 | 655.21 | 655.21 | 525.21 |
Additional Paid-In Capital | 1,588 | 1,588 | 1,571 | 1,532 | 1,495 | 636.77 |
Retained Earnings | -2,068 | -2,046 | -1,805 | -1,364 | -942.85 | -722.55 |
Comprehensive Income & Other | 5.27 | 7.69 | 17.08 | 10.91 | 7.19 | -1.06 |
Shareholders' Equity | 181.94 | 205.54 | 438.96 | 834 | 1,214 | 438.37 |
Total Liabilities & Equity | 677.59 | 705.09 | 849.13 | 1,169 | 1,497 | 648.54 |
Total Debt | 370.97 | 379.62 | 301.86 | 221.19 | 230.21 | 160.99 |
Net Cash (Debt) | 49.9 | 72.02 | 291.76 | 732.11 | 1,040 | 310.88 |
Net Cash Growth | -79.44% | -75.32% | -60.15% | -29.60% | 234.52% | -50.69% |
Net Cash Per Share | 0.08 | 0.11 | 0.44 | 1.12 | 1.79 | 0.59 |
Filing Date Shares Outstanding | 715.12 | 655.61 | 655.61 | 655.21 | 655.21 | 525.21 |
Total Common Shares Outstanding | 715.12 | 655.61 | 655.61 | 655.21 | 655.21 | 525.21 |
Working Capital | 307.72 | 398.08 | 536.37 | 917.61 | 1,255 | 415.39 |
Book Value Per Share | 0.25 | 0.31 | 0.67 | 1.27 | 1.85 | 0.83 |
Tangible Book Value | 181.13 | 204.59 | 437.28 | 832.07 | 1,212 | 437.53 |
Tangible Book Value Per Share | 0.25 | 0.31 | 0.67 | 1.27 | 1.85 | 0.83 |
Machinery | - | 14.8 | 14.41 | 14.18 | 11.75 | 6.01 |
Construction In Progress | - | - | - | - | - | 15.65 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.